Document is current

Article History

Received: 8 September 2025

Accepted: 26 November 2025

First Online: 12 December 2025

Declarations

:

: Martin Schaller reports grants and personal fees from Galderma, personal fees from Abbvie, personal fees from Bayer Healthcare, personal fees from InfectoPharm, personal fees from Lilly, outside of the submitted work. Belinda Welsh reports advisory and speaker roles for Galderma and Candela. Giuseppe Micali reports advisory speaker roles for Eli Lilly, UCB, Pfizer and Incyte. Jerry Tan reports advisory, consultant and speaker roles for Avene, Bausch, Boots Walgreens, Galderma, L’Oreal and Sun Pharma. James Del Rosso reports clinical research investigator*, consultancy/ advisory^ and speaker # roles for AbbVie^ # , Aclaris*^ # , Almirall*, Amgen (Celgene)*^ # , Anaptys Bio*, Apogee Therapeutics*, Arcutis*^, Aslan*^, Athenex*, Bausch (Ortho Dermatology)*^ # , Beiersdorf^ # , Biofrontera^*, Biopharmx*^, Biorasi*, Blue Creek^, Botanix*, Bristol Myers Squibb*^ # , Cage Bio*, Cara Therapeutics*, Cassiopea*^, Dermata^ Dermavant^*, Encore^*, EPI Health*^ # , Evommune*^, Ferndale^*, Galderma*^ # , Genentech* # ,Incyte*^ # , Janssen*, Johnson & Johnson^, La Roche Posay^, LEO Pharma*^ # , Lilly*^ # , L’Oréal^, MC2^, Moonlake*, Nektar*, Novan *^, Nutrafol^, Pfizer*^ # , Ralexar*, RBC Consultants^, Regeneron*^ # , Sanofi-Genzyme^*, Sente^, Solgel*^, Sonoma (Intraderm)^, Sun Pharma*^ # , Takeda*^, UCB*^ # , Verrica^* and Vyne # . Julie Harper reports advisory and speaker roles for Almirall, Arcutis Biotherapeutics, Bioderma, Beiersdorf, Bubble Beauty Inc, Cutera, Galderma, Journey Medical Corporation, L’Oréal, Nutrafol, Ortho Dermatologics, Pelthos Therapeutics, Sagimet Biosciences, Sanofi and Sun Pharma. Thomas Dirschka reports research support for Abbvie, Almirall, Biofrontera, Damae, Emblation, Galderma, Intros, ISDIN, La Roche Posay, L ‘Óreal, Mylan, Nordberg, Olistic, Schulze & Böhm GmbH, Scibase S.A., Smartinmedia AG, Speclipse, and Vichy. Lectures for Aesclepion, Almirall, Biofrontera, Damae, Dr. August Wolff, Galderma, GSK, Infectopharm, Intros, Janssen-Cilag, Leo, Louis Widmer, Mylan, Neracare, Nordberg, Novartis, Pierre Fabre, Pfizer, Riemser, Speclipse, and UCB. Member of advisory boards for Almirall, Beiersdorf, Biofrontera, GSK, Dr. Pfleger, Galderma, Janssen-Cilag, Leo, Mylan, Neracare, Nordberg, Novartis, Pierre Fabre, Scibase, Smart In Media AG, and Vichy. Soyun Cho has nothing to disclose. Luiz MC Almeida has nothing to disclose. Wioletta Barańska-Rybak reports advisory and speaker roles for Galderma. Johannes Dayrit reports speaker roles for Isispharma. Linda Stein Gold reports advisory, investigator and speaker roles for Galderma, Almirall, Journey Medical Corporation, Ortho Dermatologics and Sun Pharma. Khen Kon is an employee of Galderma.

: This article does not involve any new studies with human participants or animals conducted by the authors. Written informed consent was obtained from all patients featured in the clinical case studies for the publication of any potentially identifiable data or images.

: This framework was conceived and developed by the Rosacea–Expert Advice on Combined and Holistic approaches (REACH) Global Scientific Committee (GSC) across three meetings, which included Martin Schaller, Belinda Welsh, Giuseppe Micali, Jerry Tan, James Del Rosso, Julie Harper, Thomas Dirschka, Soyun Cho, Luiz MC Almeida, Wioletta Barańska-Rybak, Johannes Dayrit, and Linda Stein Gold.